

Cover Story
Conversation with The Cancer Letter
FDA officials said the questions about accelerated approval of PD-1 and PD-L1 drugs have been largely resolved, thanks in part to guidance from the Oncologic Drugs Advisory Committee.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- ODAC Confidential: The seven deadly sins sponsors commit again and again at FDA presentations
- C. David Allis, pioneer of chromatin biology and epigenetics, dies at 71
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research
- Ignore at your own risk: FDA draft guidance puts flashing lights around “dose optimization”
- Epigeneticists may be looking for epigenome-disease associations in the wrong place